KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Treasury Shares (2021 - 2025)

Historic Treasury Shares for Bionano Genomics (BNGO) over the last 5 years, with Q3 2025 value amounting to $3590.0.

  • Bionano Genomics' Treasury Shares fell 9913.08% to $3590.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3590.0, marking a year-over-year decrease of 9913.08%. This contributed to the annual value of $6000.0 for FY2024, which is 5000.0% up from last year.
  • Latest data reveals that Bionano Genomics reported Treasury Shares of $3590.0 as of Q3 2025, which was down 9913.08% from $4160.0 recorded in Q2 2025.
  • In the past 5 years, Bionano Genomics' Treasury Shares ranged from a high of $2.5 million in Q1 2023 and a low of $3590.0 during Q3 2025
  • Over the past 5 years, Bionano Genomics' median Treasury Shares value was $248000.0 (recorded in 2023), while the average stood at $337497.5.
  • Its Treasury Shares has fluctuated over the past 5 years, first surged by 73006.76% in 2023, then tumbled by 9925.85% in 2025.
  • Quarter analysis of 5 years shows Bionano Genomics' Treasury Shares stood at $361000.0 in 2021, then crashed by 91.97% to $29000.0 in 2022, then tumbled by 86.21% to $4000.0 in 2023, then surged by 50.0% to $6000.0 in 2024, then plummeted by 40.17% to $3590.0 in 2025.
  • Its Treasury Shares was $3590.0 in Q3 2025, compared to $4160.0 in Q2 2025 and $5210.0 in Q1 2025.